Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

This study is testing a combination of nimotuzumab (a targeted drug), toripalimab (an immunotherapy), and chemotherapy as a treatment before surgery for locally advanced tonsil cancer. Researchers want to see if this combination can shrink the tumor, improve surgery outcomes, and potentially increase survival. **You may be eligible if:** - You are aged 18 to 80 - You have been confirmed by biopsy to have locally advanced tonsil squamous cell carcinoma that can be surgically removed - Your general health status is good (ECOG performance status 0–2) - You have at least one measurable tumor on scans - Your blood counts, liver, kidney, and heart function are within acceptable ranges - You are willing to use effective contraception during and after treatment - Your expected survival is at least 6 months **You may NOT be eligible if:** - You have previously received systemic treatment for this cancer - You have received prior immunotherapy (anti-PD-1/PD-L1) or EGFR-targeted drugs - You have active autoimmune disease requiring treatment - You have a serious infection, HIV, active tuberculosis, or a history of serious lung inflammation - You have had major surgery within the past 30 days - You are pregnant or breastfeeding - Your cancer has spread to the brain Talk to your doctor to see if this trial is right for you.